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under the CC BY-NC-ND license (http:Abstract With the increase in epidemic proportions of diabetes worldwide, the number of
patients who will require renal replacement therapy (RRT) will be a great challenge to the
health infrastructures of developing countries such as Nigeria. Because those mostly affected
are in the economically productive age group, a vicious circle is established whereby those who
keep the economy going are the same people affected. Secondary and tertiary care of chronic
kidney disease involving RRTwould exact disproportionate toll on the income of patients in the
developing world where patients pay out of pocket for their own care. Whilst there is an in-
crease in the number of facilities offering RRT, there is no commensurate sustainability of care
either by the patients themselves or even by the government. The level of unemployment is
increasing. Kidney transplantation is out of reach in addition to the cost of post-transplant
care, which includes hospitalization and immunosuppressive medications. Most of the end-
stage kidney disease patients who enlisted in our dialysis program were unable to get or sustain
adequate hemodialysis. The data also showed that more men were dialyzed at our facilities
over the period under review and the age distribution has not changed much over the decade.
From this dismal picture in the last decade emerges a series of questions as to why this is so
and what must be done to increase access to RRT. Prudent fund management and cost contain-
ment, local manufacture of dialysis materials and nongovernmental sources of funding are
means of driving down the cost of dialysis. In countries where drugs and equipment for health
services are locally manufactured, such as India and other countries, the cost of health care is
more affordable than in countries such as Nigeria where these are imported.
在全世界，糖尿病的盛行率與日俱增，然而對於發展中國家如尼日利亞，基礎醫療架構並不足以
應付患者對腎置換療法 (RRT) 的需求。本地民眾必須自費支付自身的醫療費用，但其收入水平遠
不足以負擔慢性腎病二級與三級照護所需的 RRT。即使目前 RRT 設施已有所增加，但無論是患
者或政府均難以維持治療的長期實施。此外，腎臟移植所需的資源在本地更是相當之有限。在被
我們納入透析計劃的末期腎病 (ESKD) 患者間，大多數並未能接受足夠或持續的透析治療。過去
十年間，在我們設施內接受透析的病人中，年齡分佈大致穩定，且男性佔較多數。目前，我們正of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
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16 S. Ajayi et al.研究如何能促進 RRT 普及實施的方案。透過謹慎的理財與成本控制、透析物料的本土生產、及非
政府資金的運用，透析的相關費用可望得以降低。目前，發展中國家如尼日利亞的藥物與醫療器
材大多仰賴進口，因此相關物資的本土生產是降低醫療成本的可行方案。The burden of chronic kidney disease in the developing
nations has engaged the attention of policy makers, health
care providers, and care givers in the developing world for
some time now, especially against the backdrop of eco-
nomic recession and prevalent poverty. Furthermore, the
population most affected by chronic kidney disease (CKD)
are those most economically productive and on whom
substantial investment has been made, due mostly to the
epidemiological pattern of CKD in the developing world.1
The World Health Organization recently listed CKD among
noncommunicable diseases that deserve attention and has
been at the vanguard of its prevention and treatment.2 At
present, regardless of the cause of CKD, most patients
present very late and the economic burden is nothing less
than catastrophic for them and their relatives.3 Renal
replacement therapy (RRT) modalities such as dialysis and
transplantation remain largely out of reach for most pa-
tients, even the most relatively well-off.4,5
The prevalence of CKD is 8e16% globally, and the num-
ber of patients on RRT is about 1.4 million in 2002, and
growing at 8% annually, it was estimated to be over 4.902
million by 2010.6e9 With the increase in epidemic pro-
portions of diabetes worldwide, the number of patients
who will require RRT will be a great challenge to the health
infrastructures of developing countries such as Nigeria.
Because those mostly affected are in the economically
productive age group, a vicious circle is established
whereby those who keep the economy going are the same
people affected.10
Much is being written about global financing of health
and catastrophic health spending in the developing world,
in which individuals and households are rendered impov-
erished by health spending. This would appear to be more
prevalent in the rural areas where the poorest in the soci-
ety live.11e13 Onwujekwe et al,12 for instance, found that a
monthly expenditure of $19.66 in certain communities in
Nigeria, an amount that is 40% of total nonfood expendi-
ture, rendered 27% of households impoverished. Urban
dwellers spend even more because the cost of living and
health is far more prohibitive.
Secondary and tertiary care of CKD involving RRT would
exact a disproportionate toll on the income of patients in
the developing world where patients pay out of pocket for
their own care. In a weak economy and poor primary health
care infrastructure for screening and prevention, RRT adds
to the burden of care and dislocates individual and family
finances.
Ten years ago, there were only 27 dialysis centers and
one transplant center in Nigeria,9 but today there are about
80 established hemodialysis (HD) enters and more than five
transplant centers, both public and private. So whilst there
is an increase in the number of facilities offering RRT, there
is no commensurate sustainability of care either by the
patients themselves or even by the government. The levelof unemployment is increasing. Kidney transplantation is
out of reach of many patients, especially when it costs a
large lump sum to get the surgery done, in addition to the
cost of post-transplant care, which includes hospitalization
and immunosuppressive medications.14
It is almost 20 years since affordability of RRT was
reviewed in our center, and it becomes necessary to revisit
the matter again. The last study from our center was a 5-
year review that concluded that over 80% of patients could
only dialyze for about 3 months.15 This means that survival
of patients with end-stage kidney disease was abysmal.
Prior to this, a similar study had found that about 70% of
patients could only afford dialysis for < 1 month.16 Very
recently, a study from another region of the country also
concluded that patients could dialyze only for about
8 weeks.17 We have undertaken a 10-year review to
determine whether there have been a change in the last
decade due to the incremental fees of dialysis and the
economic changes in the country.
The last 10 years have witnessed an increase in the
number of dialysis centers. This means that there have
been huge investments both by the government and the
private sectors. The gross domestic product (GDP) has more
than doubled since 2005, from $112 billion to $262 billion in
2012; and the gross national income per capita from $772 to
$1426.18 These figures and statistics should ordinarily yield
health benefits in terms of infrastructural development and
increased capital outlay for health spending.
In the last 10 years, the number of HD machines has
increased from 5 to 15 in Ibadan, and the cost of HD has
only marginally increased from N25,000 ($125) to N30,000
($150). There are now three dialysis centers in Ibadan, one
public and two private. We expected the number of pa-
tients admitted for maintenance dialysis to increase
significantly in the last 10 years, and therefore, we were
interested in how long patients can sustain RRT.
Records of all patients with CKD who dialyzed in the unit
from 2004 to 2013 were abstracted. The variables of in-
terest were age, sex, underlying kidney disease, number of
dialysis sessions and duration of dialysis. All patients with
acute renal failure or acute kidney injury were excluded.
Our focus was primarily to explore the duration or number
of dialysis patients can afford before dropping out of care
or death. We also assume that the rest who did not ask to
be transferred out nor had transplantation dropped out of
care for financial reasons.
A total of 956 patients were dialyzed over a period of
10 years. There were 371 women (38.9%) and 585 men
(61.1%). Hypertensive nephrosclerosis, chronic glomerulo-
nephritis (CGN), diabetic nephropathy, and obstructive
uropathy (benign prostatic hypertrophy, prostatic cancer
and urethral obstruction in males and pelvic tumors like
cervical cancer in females) account for 42.0%, 30.1%, 9.5%,
and 7.0% respectively. Human immunodeficiency virus-
Table 2 Sex distribution of causes of kidney failure.
Diagnosis Sex Age (y),
median
Age (y),
mean (SD)
n (%)
HTN Female 48.0 49.0 (14.2) 150 (15.7)
Male 50.0 51.0 (14.9) 251 (26.3)
Chronic
glomerulonephrits
Female 29.0 32.6 (14.1) 121 (12.6)
Male 30.0 32.5 (13.0) 167 (17.4)
DN Female 53.5 54.8 (12.2) 32 (3.3)
Male 56.0 56.6 (10.5) 59 (6.2)
Obstructive uropathy Female 57.0 56.0 (15.7) 21 (2.2)
Male 65.0 64.0 (13.0) 46 (4.8)
HIV nephropathy Female 37.5 39.1 (11.6) 32 (3.4)
Male 39.0 38.1 (9.6) 26 (2.7)
HTN þ DN Female 62.0 62.0 (10.0) 2 (0.2)
Male 64.0 66.2 (10.0) 19 (2.0)
HbSS nephropathy Female 25.0 21.3 (9.1) 3 (0.3)
Male 32.0 32.0 (7.1) 2 (0.2)
Others Female 47.0 44.5 (12.5) 10 (1.1)
Male 47.0 49.0 (12.1) 15 (1.6)
Total 956 (100)
DN Z diabetic nephropathy; HbSS Z hemoglobin SS; HIV Z
human immunodeficiency virus; HTN Z hypertensive nephro-
sclerosis; Other Z vasculitis, unspecified or unknown;
SD Z standard deviation.
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age was 41.1 years. The mean age of patients with hyper-
tensive nephrosclerosis is 50 years, CGN 32.5 years, and
diabetic nephropathy 56 years. There is a male prepon-
derance in the sex distribution of various underlying kidney
disease with exception of human immunodeficiency virus
(Tables 1 and 2). The mean number of days on dialysis was
21.8 and the mean number of dialysis sessions was 4.6
(Figure 1). The median of these variables are not substan-
tially different (Figure 2). This means that, overall, the
number of dialysis per week was about one. This ratio of
period on dialysis and number of dialysis sessions appears to
be roughly the same for the decade, except for the occa-
sional patient who dialyzed for a relatively long time, as for
example in 2004, when a patient dialyzed for at least a year
(Figure 1).
Our review showed that most of the end-stage renal
disease patients who enlisted in our dialysis program were
unable to get or sustain adequate HD. The data also showed
that more men were dialyzed at our facilities over the
period under review and the age distribution has not
changed much over the decade. Reasons adduced for male
preponderance generally in seeking health care and ac-
counting for more hospital admission than females include
higher level of education in males, cultural practices that
favor males, and higher incomes. Men are bread-winners,
and therefore are more likely to get more attention and the
necessary support from family members. The prevalence of
hypertension in the population is about the same in men
and women,19 but when complications occur, men are more
likely to get attention in the largely traditional settings in
Nigeria. This may account for the higher prevalence of male
patients with kidney disease and even diabetes mellitus in
hospital data.20,21
From this dismal picture in the last decade emerges a
series of questions as to why this is so and what must be
done to increase access to renal replacement therapy.
Besides, without a reliable and affordable dialysis program,
even a transplant program would be in jeopardy.
The common problems are poverty, accessibility to
dialysis centers, and inadequate government support forTable 1 Distribution of the underlying kidney disease.
Diagnosis Age (y),
median
Age (y),
mean (SD)
n (%)
HTN 49 50.0 (14.7) 401 (42.0)
Chronic
glomerulonephrits
30 32.5 (13.4) 288 (30.1)
DN 55 56.0 (11.1) 91 (9.5)
Obstructive uropathy 65 61.5 (14.3) 67 (7.0)
HIV nephropathy 38 38.7 (10.7) 58 (6.1)
HTN þ DN 64 65.8 (9.4) 21 (2.2)
HbSS nephropathy 27 25.6 (9.4) 5 (0.5)
Other 47 47.2 (12.2) 25 (2.6)
Total 956 (100)
DN Z diabetic nephropathy; HbSS Z hemoglobin SS; HIV Z
human immunodeficiency virus; HTN Z hypertensive nephro-
sclerosis; Other Z vasculitis, unspecified or unknown;
SD Z standard deviation.renal replacement.10,17,22 Nigeria is now ranked the biggest
economy in Africa, due to its increasing GDP over the years,
but the economic gains, as in most developing nations
lacking structured social security, has not trickled down to
the general population. The GDP in 2013 stood at $521.8
billion compared to South Africa’s $350.5 billion; however,
the poverty headcount ratio at national poverty line is 46%
of the population, or more.23 The economy is characterized
by the fact that a large proportion of population is not
benefiting from the economic growth.24 Individual eco-
nomic empowerment is low, and without government sub-
sidy and meaningful health insurance, many people
requiring renal replacement therapy would not be able to
afford it.Figure 1 Mean age, number of days on dialysis, and number
of dialysis sessions.
Figure 2 Median of age, number of days on dialysis, and
number of dialysis sessions.
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least 100 km offering HD (Lagos, Ile-Ife, and Abeokuta) and
not more than three centers in any of these cities. Today,
the number has increased and there are even private
dialysis centers in many cities. One would expect that
accessibility to care and sustainability would improve, but
this is apparently not the case, because of cost, which is
paid for out-of-pocket.What should be done?
It has been suggested that, because HD is expensive, in
poor economies, the financial capability of patients to
sustain dialysis for an extended period should be one of the
criteria for acceptance into the program.25 This will be
difficult to implement in a culturally sensitive environment
where care-givers never want to abandon their relatives
even if they have to borrow to pay the hospital bills.
RRT is a capital intensive project, and therefore,
without government support or subsidy, the majority of
patients in resource-poor settings would not be able to pay
for it. Health insurance is another way to enhance afford-
ability. However, in Nigeria today, neither government
subsidy nor robust and comprehensive health insurance are
available. The cost of health care is borne by the patients
or their relatives. There is no funding mechanism to reim-
burse the provider. Indeed, the only effort to provide care
by public hospitals is through a mechanism of users’ fee
revolving system whereby the money paid by the patients is
deposited in a dedicated account and used to purchase
consumables for the next round of dialysis. The government
does not provide subsidies or reimbursement for dialysis.
Indeed, a few private dialysis facilities have been set up in
big commercial cities in Nigeria, and because they are
largely profit-making concerns, only rich patients can
afford care in these centers. The only advantage is that
these centers are better managed to provide continuity of
care for those who can afford it. Therefore, are exist dif-
ferences in the fees in dialysis centers, although sometimes
marginal. Currently, the best the government has offered
through the recently established National Health InsuranceScheme (NHIS) for RRT are six sessions of HD, ostensibly for
acute kidney injury. The Nigerian Association of Nephrology
is engaging the NHIS in this regard. The association advo-
cates increased funding for the NHIS to be able to take on
more chronic kidney disease patients on requiring RRT.
Government subsidy and reimbursement will substantially
improve access to RRT. A state government, due to strong
advocacy, has offered dialysis at highly subsidized fees and
in some cases free of charge.
Today, there is no hospital in Nigeria offering peritoneal
dialysis (PD) for patients with end-stage kidney disease on a
regular and continuous basis, even though the overall cost of
PD and HD may approximate because of pricing due to the
fact that all materials for dialysis are imported. However,
this is about choice and an alternative driving down the cost.
It seems more profitable for the industry to promote HD,
whilst recognizing the usual reason of peritonitis for not
doing more PD. Middle men inflate the cost of these ma-
chines, and there is little hard bargaining because of the
contract nature of procurement. For instance, it is possible
for a company, and this has been done in some centers, to
supply the hardware ex gratia, and then make their profit
from supplies of dialyzers, blood lines, salt, etc. This has
been known to reduce the cost considerably. This arrange-
ment also improved the maintenance of the machines
because such companies undertake to maintain them
instead of waiting for public institutions and bureaucracy.
Recently, the Nigerian Association of Nephrology engaged
some intravenous fluid manufacturers to also produce fluids
for PD. They agreed on the condition that there would be
demand for the fluids to justify investment. Consequently,
the association used the forum of its annual general and
scientificmeeting 1 year ago to emphasize the need for PD by
dedicating a whole day under a subtheme to discuss PD. The
International Society of Nephrology Continuing Medical Ed-
ucation committee sponsored an international speaker for
this purpose. A committee on PD was then set up by the as-
sociation to find ways to encourage the use of PD. Some
centers have recommenced use of PD, especially for chil-
dren. The main difficulty is occurrence of peritonitis, but
with best practices guidelines, this difficulty is being over-
come and the outcome is better.26e28
Most of our patients typically present in emergencies,
especially pulmonary edema, and are dialyzed using tem-
porary access through neck lines, and when suitable cathe-
ters are not available, femoral lines, which we seriously
discourage now. The neck lines are only now being stocked in
the hospital, and patients have had to procure these from
private vendors. More centers now increasingly perform fis-
tula procedures at a cost ranging from $100 to $200. Local
transplant surgeons and International Society of Nephrology
(ISN) educational ambassadors have conducted training in
some centers in Nigeria.
If the burden of chronic noncommunicable diseases can
be reduced by preventive and screening programs, more
funds may be available for RRT. In addition, a functional
donor and transplant program will reduce substantially the
number of patients dependent on dialysis. Local manufac-
ture of dialysis machines and consumables and generic
drugs will make dialysis more affordable. At the moment,
all dialysis hardware and consumables are imported
Renal replacement therapy in Nigeria 19without any import duties waiver, and this has added to the
increase in cost of dialysis.
Conclusion
HD, and indeed RRT, is still out of reach of most patients
requiring it in Nigeria and this has gone on for too long in
spite of the increase in national wealth and increase in the
number of facilities where hemodialysis is offered. Most
patients cannot afford dialysis for more than a few weeks.
Prudent fund management and cost containment, local
manufacture of dialysis materials and nongovernmental
sources of funding are means of driving down the cost of
dialysis.8 In countries where drugs and equipment for
health services are locally manufactured, such as India, the
cost of health care is generally affordable.
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